In an era of resurgent interest in integrative oncology, the EAGER trial offers compelling, data-driven evidence that electro-acupuncture can preserve quality of life and extend disease-free survival in gastric cancer patients. The finding challenges conventional boundaries between traditional medicine and rigorous clinical science.
Chinese scientists have demonstrated that electro-acupuncture, a modern adaptation of traditional needle therapy, can substantially improve the quality of life for patients undergoing adjuvant chemotherapy for gastric cancer. Published as a randomized, multicenter trial across 11 hospitals in China, the study known as the Electro-Acupuncture in Gastric Cancer (EAGER) trial assigned 222 patients with stage II–III cancer to receive high-frequency electro-acupuncture, low-frequency electro-acupuncture, or no electro-acupuncture during the first three cycles of chemotherapy after gastrectomy.
The results were striking. The health-related quality of life, measured by the Functional Assessment of Cancer Therapy-Gastric Trial Outcome Index, was significantly higher in both electro-acupuncture groups than in the usual-care group. More importantly, electro-acupuncture was associated with prolonged disease-free survival, with hazard ratios of 0.47 and 0.51 for high-frequency and low-frequency groups, respectively. Patients receiving electro-acupuncture also experienced fewer grade 3–4 adverse events and exhibited reduced levels of peripheral myeloid-derived suppressor cells, suggesting an immunological mechanism. Dosing frequency did not affect outcomes, implying a threshold effect.
These findings are significant not only for China, where gastric cancer remains one of the most common malignancies, but for global oncology. The trial provides rare, randomized evidence that a traditional non-pharmacologic intervention can influence hard endpoints such as survival, not just subjective well-being. For healthcare system researchers studying Integrative Medicine in China, the EAGER trial signals a maturing evidence base that could reshape clinical guidelines and insurance coverage decisions for acupuncture-based supportive care.
Why it matters:
The EAGER trial provides high-level evidence that electro-acupuncture is a clinically meaningful adjunct to chemotherapy in gastric cancer, showing improvements in both quality of life and survival. For healthcare researchers and policymakers, this suggests that traditional methods, when rigorously tested, can offer scalable, low-toxicity interventions that complement existing cancer treatment pathways. The immunological findings also open a new avenue for understanding how non-pharmacologic therapies may modulate the tumor microenvironment.
ScientificChina — tracking what’s happening in Chinese science, technology, research, and industrial innovation in a way global professionals can actually use.
Follow ScientificChina for deeper insight into China’s evolving science, technology, and industrial landscape.
No products in the cart.